NCT02612545View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia

PHASE1CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

October 12, 2018

Study Completion Date

October 8, 2019

Conditions
Acute Falciparum Malaria
Interventions
DRUG

Dihydroartemisinin-piperaquine (DHA-PPQ)

Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia

DRUG

Mefloquine (MQ)

ACT partner drug

Trial Locations (1)

Unknown

National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H, Phnom Penh

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02612545 - Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia | Biotech Hunter | Biotech Hunter